Top 3 High Growth Tech Stocks In Hong Kong To Watch

In This Article:

As global markets show signs of optimism, with the Hang Seng Index up 1.99% and technology stocks leading gains, Hong Kong's tech sector is drawing significant investor attention. In this dynamic environment, identifying high-growth tech stocks requires a keen eye on companies that are not only innovating but also demonstrating strong fundamentals and market adaptability.

Top 10 High Growth Tech Companies In Hong Kong

Name

Revenue Growth

Earnings Growth

Growth Rating

Wasion Holdings

22.71%

25.80%

★★★★★☆

Be Friends Holding

33.82%

32.27%

★★★★★★

MedSci Healthcare Holdings

45.88%

45.90%

★★★★★☆

Inspur Digital Enterprise Technology

21.83%

38.02%

★★★★★☆

iDreamSky Technology Holdings

29.81%

104.11%

★★★★★★

Cowell e Holdings

30.96%

35.72%

★★★★★★

RemeGen

26.30%

52.19%

★★★★★☆

Innovent Biologics

21.21%

50.78%

★★★★★☆

Biocytogen Pharmaceuticals (Beijing)

21.35%

100.10%

★★★★★☆

Beijing Airdoc Technology

31.64%

83.90%

★★★★★☆

Click here to see the full list of 47 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Biocytogen Pharmaceuticals (Beijing)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of antibody-based drugs, operating in China, the United States, and internationally, with a market cap of HK$2.52 billion.

Operations: Biocytogen Pharmaceuticals generates revenue primarily from animal model sales (CN¥293.68 million), pre-clinical pharmacology and efficacy evaluation (CN¥193.40 million), antibody development (CN¥175.87 million), and gene editing services (CN¥74.33 million).

Biocytogen Pharmaceuticals (Beijing) has demonstrated impressive growth, with revenue increasing by 34.3% over the past year and forecasted to grow at 21.3% annually, outpacing the Hong Kong market's 7.4%. The company's substantial R&D investments have resulted in a robust pipeline, including a recent agreement with IDEAYA Biosciences for a potential $406.5 million in milestone payments and royalties from their B7H3/PTK7 BsADC program. Additionally, Biocytogen's antibody licensing business and innovative animal models continue to drive revenue, contributing significantly to its promising financial outlook despite current unprofitability.

SEHK:2315 Revenue and Expenses Breakdown as at Aug 2024

Wasion Holdings

Simply Wall St Growth Rating: ★★★★★☆